ClinicalTrials.gg
CompletedNCT05718648Updated Nov 28, 2025Results posted

A Study to Test How BI 1015550 is Taken up in the Blood of People With and Without Kidney Problems

A Phase 1 interventional study of BI 1015550 in Renal Insufficiency and Healthy, sponsored by Boehringer Ingelheim. Completed at 1 site in Germany. Open to participants aged 18 Years to 79 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-11-28.

Sponsored by Boehringer Ingelheim · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
26
Allocation
Non-randomized
Ages
18 Years to 79 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies in Renal Insufficiency by Boehringer Ingelheim — none open to participants now, none under way, none of them phase 3. Renal Insufficiency · Boehringer Ingelheim.

Enrollment
8th of 11
26 · median 35
Started
2023
with 1 other
Phase 1
10 of 11
none open now
Registered
9th of 11
by date

Among the 11 studies in Renal Insufficiency by Boehringer Ingelheim, this one is the 8th largest by enrollment, is one of 2 that started in 2023, is one of 10 in phase 1, and was the 9th registered.

Renal Insufficiency

1,413 studies on the registry are indexed under Renal Insufficiency; 146 are open to participants now.

Browse Renal Insufficiency studies →

Open to participants now

None of the 11 studies in Renal Insufficiency by Boehringer Ingelheim is open now. The open studies under Renal Insufficiency, anywhere →

Who these studies take

Of the 92 Renal Insufficiency studies recruiting now, 48 (52%) set no upper age limit and 19 (21%) stop at 75 or younger; 8 take children under 18; 15 take healthy volunteers.

This study: 18 Years to 79 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 11 studies in Renal Insufficiency by Boehringer Ingelheim as a file.
02

Study summary

This study is open to adults aged 18 years and older. People without kidney problems and people who have moderate or severe kidney problems can join the study.

The purpose of this study is to find out how a medicine called BI 1015550 is taken up in the blood of people with and without kidney problems. Kidney problems may change how a medicine is taken up in the blood. All participants take a single tablet of BI 1015550.

Participants are in the study for about 2 weeks. During this time, they visit the study site 6 times. On the second visit, participants stay overnight at the study site for 4 nights. At the visits, doctors take blood samples to measure the levels of BI 1015550 in participants' blood. Then they compare the results between the groups of participants with and without kidney problems. The doctors also check participants' health and take note of any unwanted effects.

03

Conditions studied

  • Renal Insufficiency
  • Healthy

Browse trials for

04

Who can participate

Ages eligible
18 Years to 79 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Inclusion Criteria:

Inclusion criteria applying to all participants:

  • Male or female participants
  • Age of 18-79 years (inclusive)
  • (BMI) of 18.5 to 35.0 kg/m2 (inclusive)
  • Signed and dated written in accordance with International Council for Harmonisation-Good Clinical Practice (ICH-GCP) and local legislation prior to admission to the trial
  • Male participants are not required to use
  • Women of (WOCBP) are allowed to participate provided they use a highly effective contraception from at least 30 days before the administration of trial medication until 7 days after trial completion.

Of note, oral hormonal contraceptives are not considered as highly effective in this study due to the potential induction by BI 1015550. Therefore, the following methods of contraception are considered adequate for female participants of childbearing potential:

  • Use of combined (oestrogen and progestogen containing) hormonal contraception that prevents ovulation (oral, intravaginal or transdermal), plus condom
  • Use of progestogen-only hormonal contraception that inhibits ovulation (only injectables or implants), plus condom
  • Use of intrauterine device (IUD) or intrauterine hormone-releasing system (IUS)
  • Sexually abstinent
  • A vasectomised sexual partner who received medical assessment of the surgical success (documented absence of sperm) and provided that partner is the sole sexual partner of the trial participant.

Female participants are not considered to be of childbearing potential if they are either surgically sterilised (including hysterectomy) or , defined as no menses for 1 year without an alternative medical cause (in questionable cases, a blood sample with levels of Follicle stimulating hormone (FSH) above 40 units per liter (U/L) and oestradiol below 30 nanograms/liter (ng/L) is confirmatory).

Further inclusion criteria apply.

Exclusion Criteria:

Exclusion criteria applying to all participants:

  • Any evidence of a concomitant disease assessed as by the investigator
  • Cholecystectomy or other surgery of the gastrointestinal (GI) tract that could interfere with the pharmacokinetics of the trial medication (except appendectomy or simple hernia repair)
  • Diseases of the central nervous system (CNS) (including but not limited to any kind of seizures or stroke), and other relevant neurological or psychiatric disorders (including but not limited to major depressive disorder)
  • History of relevant orthostatic hypotension, fainting spells, or blackouts
  • Relevant chronic or acute infections
  • Any documented active or suspected or history of malignancy within 5 years prior to screening, except appropriately treated basal cell carcinoma of the skin or squamous cell carcinoma in situ of the skin or in situ carcinoma of uterine cervix
  • History of relevant allergy or (including allergy to the trial medication or its )
  • Use of drugs within 30 days (or 5 of their half-lives, whichever is longer) of planned administration of trial medication that might reasonably influence the results of the trial (including drugs that cause /QT interval corrected for heart rate (QTc) interval prolongation) Further exclusion criteria apply.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
26 participants (actual)

Study arms

  • Experimental
    BI 1015550 Severe renal impairment

    Participants with severe renal impairment (estimated glomerular filtration rate (eGFR)) according to Chronic Kidney Disease Epidemiology Collaboration 15-29 milliliter(mL)/minute(min)/1.73 meter(m)²), and not requiring dialysis, administered orally one film-coated tablet of 18 milligram (mg) of BI 1015550 with 240 mL of water after an overnight fast of at least 10 hours (h).

    Drug: BI 1015550

  • Experimental
    BI 1015550 Moderate renal impairment

    Participants with moderate renal impairment (eGFR 30-59 mL/min/1.73 m²) administered orally one film-coated tablet of 18 mg of BI 1015550 with 240 mL of water after an overnight fast of at least 10 h.

    Drug: BI 1015550

  • Experimental
    BI 1015550 Normal renal function

    Participants with normal renal function (eGFR ≥90 mL/min/1.73 m²) administered orally one film-coated tablet of 18 mg of BI 1015550 with 240 mL of water after an overnight fast of at least 10 h. Participants with normal renal function were individually matched by age (± 10 years), gender, weight (± 15%), and race to the participants with renal impairment. Each participant with normal renal function could be matched to one participant with moderate renal impairment and to one participant with severe renal impairment.

    Drug: BI 1015550

Interventions

  • BI 1015550

    Also known as: Nerandomilast, JASCAYD®

06

What researchers measure

Primary outcomes

  1. Area Under the Concentration-time Curve of R-BI 1015550 in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz)

    Area under the concentration-time curve of R-BI 1015550 (the pharmacologically active R-enantiomer, measured by a chiral assay) in plasma over the time interval from 0 to the last quantifiable data point (AUC0-tz) is reported. Geometric least square mean (adjusted geometric mean) and adjusted geometric standard error were calculated using an analysis of variance (ANOVA) model on the logarithmic scale. The pharmacokinetic (PK) endpoints were log-transformed (natural logarithm) prior to fitting the ANOVA model. This model included effects accounting for the following sources of variation: 'degree of renal impairment' as fixed effect as well as 'matched pair' as random effect. These quantities were then back-transformed to the original scale. The ratio of adjusted geometric means is calculated with patients with renal impairment as test groups and their respective matched controls as reference groups.

    Time frame: Within 2 hours (h) prior to drug administration and 0.5, 0.75, 1, 1.25, 1.5, 1.75, 2, 2.5, 3, 4, 6, 8, 10, 12, 14, 24, 36, 48, 72, 96, 120 and 144 h after drug administration.

  2. Area Under the Concentration-time Curve of BI 1015550 in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz)

    Area under the concentration-time curve of BI 1015550 (mixture of R-(pharmacologically active) and S-(pharmacologically inactive) enantiomers, measured by a non-chiral assay) in plasma over the time interval from 0 to the last quantifiable data point (AUC0-tz) is reported. Geometric least square mean (adjusted geometric mean) and adjusted geometric standard error were calculated using an analysis of variance (ANOVA) model on the logarithmic scale. The pharmacokinetic (PK) endpoints were log-transformed (natural logarithm) prior to fitting the ANOVA model. This model included effects accounting for the following sources of variation: 'degree of renal impairment' as fixed effect as well as 'matched pair' as random effect. These quantities were then back-transformed to the original scale. The ratio of adjusted geometric means is calculated with patients with renal impairment as test groups and their respective matched controls as reference groups.

    Time frame: Within 2 hours (h) prior to drug administration and 0.5, 0.75, 1, 1.25, 1.5, 1.75, 2, 2.5, 3, 4, 6, 8, 10, 12, 14, 24, 36, 48, 72, 96, 120 and 144 h after drug administration.

  3. Maximum Measured Concentration of R-BI 1015550 in Plasma (Cmax)

    Maximum measured concentration of R-BI 1015550 (the pharmacologically active R-enantiomer, measured by a chiral assay) in plasma (Cmax) is reported. Geometric least square mean (adjusted geometric mean) and adjusted geometric standard error were calculated using an analysis of variance (ANOVA) model on the logarithmic scale. The pharmacokinetic (PK) endpoints were log-transformed (natural logarithm) prior to fitting the ANOVA model. This model included effects accounting for the following sources of variation: 'degree of renal impairment' as fixed effect as well as 'matched pair' as random effect. These quantities were then back-transformed to the original scale. The ratio of adjusted geometric means is calculated with patients with renal impairment as test groups and their respective matched controls as reference groups.

    Time frame: Within 2 hours (h) prior to drug administration and 0.5, 0.75, 1, 1.25, 1.5, 1.75, 2, 2.5, 3, 4, 6, 8, 10, 12, 14, 24, 36, 48, 72, 96, 120 and 144 h after drug administration.

  4. Maximum Measured Concentration of BI 1015550 in Plasma (Cmax)

    Maximum measured concentration of BI 1015550 (mixture of R-(pharmacologically active) and S-(pharmacologically inactive) enantiomers, measured by a non-chiral assay) in plasma (Cmax) is reported. Geometric least square mean (adjusted geometric mean) and adjusted geometric standard error were calculated using an analysis of variance (ANOVA) model on the logarithmic scale. The pharmacokinetic (PK) endpoints were log-transformed (natural logarithm) prior to fitting the ANOVA model. This model included effects accounting for the following sources of variation: 'degree of renal impairment' as fixed effect as well as 'matched pair' as random effect. These quantities were then back-transformed to the original scale. The ratio of adjusted geometric means is calculated with patients with renal impairment as test groups and their respective matched controls as reference groups.

    Time frame: Within 2 hours (h) prior to drug administration and 0.5, 0.75, 1, 1.25, 1.5, 1.75, 2, 2.5, 3, 4, 6, 8, 10, 12, 14, 24, 36, 48, 72, 96, 120 and 144 h after drug administration.

Secondary outcomes

  1. Area Under the Concentration-time Curve of R-BI 1015550 in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞)

    Area under the concentration-time curve of R-BI 1015550 (the pharmacologically active R-enantiomer, measured by a chiral assay) in plasma over the time interval from 0 extrapolated to infinity (AUC0-∞) is reported. Geometric least square mean (adjusted geometric mean) and adjusted geometric standard error were calculated using an analysis of variance (ANOVA) model on the logarithmic scale. The pharmacokinetic (PK) endpoints were log-transformed (natural logarithm) prior to fitting the ANOVA model. This model included effects accounting for the following sources of variation: 'degree of renal impairment' as fixed effect as well as 'matched pair' as random effect. These quantities were then back-transformed to the original scale. The ratio of adjusted geometric means is calculated with patients with renal impairment as test groups and their respective matched controls as reference groups.

    Time frame: Within 2 hours (h) prior to drug administration and 0.5, 0.75, 1, 1.25, 1.5, 1.75, 2, 2.5, 3, 4, 6, 8, 10, 12, 14, 24, 36, 48, 72, 96, 120 and 144 h after drug administration.

  2. Area Under the Concentration-time Curve of BI 1015550 in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞)

    Area under the concentration-time curve of BI 1015550 (mixture of R-(pharmacologically active) and S-(pharmacologically inactive) enantiomers, measured by a non-chiral assay) in plasma over the time interval from 0 extrapolated to infinity (AUC0-∞) is reported. Geometric least square mean (adjusted geometric mean) and adjusted geometric standard error were calculated using an analysis of variance (ANOVA) model on the logarithmic scale. The pharmacokinetic (PK) endpoints were log-transformed (natural logarithm) prior to fitting the ANOVA model. This model included effects accounting for the following sources of variation: 'degree of renal impairment' as fixed effect as well as 'matched pair' as random effect. These quantities were then back-transformed to the original scale. The ratio of adjusted geometric means is calculated with patients with renal impairment as test groups and their respective matched controls as reference groups.

    Time frame: Within 2 hours (h) prior to drug administration and 0.5, 0.75, 1, 1.25, 1.5, 1.75, 2, 2.5, 3, 4, 6, 8, 10, 12, 14, 24, 36, 48, 72, 96, 120 and 144 h after drug administration.

07

Results

Posted Nov 28, 2025

Participant flow

This Phase I trial applied a non-randomised, parallel matched-group design and included participants with moderate or severe renal impairment and participants with normal renal function (matched controls to participants with renal impairment). All trial participants received one 18 milligram BI 1015550 tablet, administered in the fasting state.

Participant flow — Overall Study
MilestoneBI 1015550 Severe renal impairmentBI 1015550 Moderate renal impairmentBI 1015550 Normal renal function
Started8810
Treated8810
Completed8810
Not completed000

Outcome measures

PrimaryArea Under the Concentration-time Curve of R-BI 1015550 in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz)

Area under the concentration-time curve of R-BI 1015550 (the pharmacologically active R-enantiomer, measured by a chiral assay) in plasma over the time interval from 0 to the last quantifiable data point (AUC0-tz) is reported. Geometric least square mean (adjusted geometric mean) and adjusted geometric standard error were calculated using an analysis of variance (ANOVA) model on the logarithmic scale. The pharmacokinetic (PK) endpoints were log-transformed (natural logarithm) prior to fitting the ANOVA model. This model included effects accounting for the following sources of variation: 'degree of renal impairment' as fixed effect as well as 'matched pair' as random effect. These quantities were then back-transformed to the original scale. The ratio of adjusted geometric means is calculated with patients with renal impairment as test groups and their respective matched controls as reference groups.

Time frame:
Within 2 hours (h) prior to drug administration and 0.5, 0.75, 1, 1.25, 1.5, 1.75, 2, 2.5, 3, 4, 6, 8, 10, 12, 14, 24, 36, 48, 72, 96, 120 and 144 h after drug administration.
Reported as:
Geometric least squares mean · hour*nanomole/Liter
Area Under the Concentration-time Curve of R-BI 1015550 in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz)
hour*nanomole/LiterBI 1015550 Severe renal impairmentBI 1015550 Normal renal function matched to severe renal impairmentBI 1015550 Moderate renal impairmentBI 1015550 Normal renal function matched to moderate renal impairment
Area Under the Concentration-time Curve of R-BI 1015550 in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz)3347.73 ± NA2590.32 ± NA3141.86 ± NA2285.92 ± NA
Statistical analysis
  • BI 1015550 Severe renal impairment vs BI 1015550 Normal renal function matched to severe renal impairment · Ratio of adjusted geometric means [%]: 129.24 · 90% CI 91.62 to 182.31Ratio \[%\] = (adjusted geometric mean of severe renal impairment / adjusted geometric mean matching control)\*100. Intra-matched pair geometric coefficient of variation (gCV) \[%\] = 37.5
  • BI 1015550 Moderate renal impairment vs BI 1015550 Normal renal function matched to moderate renal impairment · Ratio of adjusted geometric means [%]: 137.44 · 90% CI 89.06 to 212.12Ratio \[%\] = (adjusted geometric mean of moderate renal impairment / adjusted geometric mean matching control)\*100. Intra-matched pair geometric coefficient of variation (gCV) \[%\] = 52.4
PrimaryArea Under the Concentration-time Curve of BI 1015550 in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz)

Area under the concentration-time curve of BI 1015550 (mixture of R-(pharmacologically active) and S-(pharmacologically inactive) enantiomers, measured by a non-chiral assay) in plasma over the time interval from 0 to the last quantifiable data point (AUC0-tz) is reported. Geometric least square mean (adjusted geometric mean) and adjusted geometric standard error were calculated using an analysis of variance (ANOVA) model on the logarithmic scale. The pharmacokinetic (PK) endpoints were log-transformed (natural logarithm) prior to fitting the ANOVA model. This model included effects accounting for the following sources of variation: 'degree of renal impairment' as fixed effect as well as 'matched pair' as random effect. These quantities were then back-transformed to the original scale. The ratio of adjusted geometric means is calculated with patients with renal impairment as test groups and their respective matched controls as reference groups.

Time frame:
Within 2 hours (h) prior to drug administration and 0.5, 0.75, 1, 1.25, 1.5, 1.75, 2, 2.5, 3, 4, 6, 8, 10, 12, 14, 24, 36, 48, 72, 96, 120 and 144 h after drug administration.
Reported as:
Geometric least squares mean · hour*nanomole/Liter
Area Under the Concentration-time Curve of BI 1015550 in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz)
hour*nanomole/LiterBI 1015550 Severe renal impairmentBI 1015550 Normal renal function matched to severe renal impairmentBI 1015550 Moderate renal impairmentBI 1015550 Normal renal function matched to moderate renal impairment
Area Under the Concentration-time Curve of BI 1015550 in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz)4367.05 ± NA3312.70 ± NA3841.47 ± NA3014.58 ± NA
Statistical analysis
  • BI 1015550 Severe renal impairment vs BI 1015550 Normal renal function matched to severe renal impairment · Ratio of adjusted geometric means [%]: 131.83 · 90% CI 93.32 to 186.22Ratio \[%\] = (adjusted geometric mean of severe renal impairment / adjusted geometric mean matching control)\*100. Intra-matched pair geometric coefficient of variation (gCV) \[%\] = 37.7
  • BI 1015550 Moderate renal impairment vs BI 1015550 Normal renal function matched to moderate renal impairment · Ratio of adjusted geometric means [%]: 127.43 · 90% CI 85.92 to 188.99Ratio \[%\] = (adjusted geometric mean of moderate renal impairment / adjusted geometric mean matching control)\*100. Intra-matched pair geometric coefficient of variation (gCV) \[%\] = 43.5
PrimaryMaximum Measured Concentration of R-BI 1015550 in Plasma (Cmax)

Maximum measured concentration of R-BI 1015550 (the pharmacologically active R-enantiomer, measured by a chiral assay) in plasma (Cmax) is reported. Geometric least square mean (adjusted geometric mean) and adjusted geometric standard error were calculated using an analysis of variance (ANOVA) model on the logarithmic scale. The pharmacokinetic (PK) endpoints were log-transformed (natural logarithm) prior to fitting the ANOVA model. This model included effects accounting for the following sources of variation: 'degree of renal impairment' as fixed effect as well as 'matched pair' as random effect. These quantities were then back-transformed to the original scale. The ratio of adjusted geometric means is calculated with patients with renal impairment as test groups and their respective matched controls as reference groups.

Time frame:
Within 2 hours (h) prior to drug administration and 0.5, 0.75, 1, 1.25, 1.5, 1.75, 2, 2.5, 3, 4, 6, 8, 10, 12, 14, 24, 36, 48, 72, 96, 120 and 144 h after drug administration.
Reported as:
Geometric least squares mean · nanomole/Liter
Maximum Measured Concentration of R-BI 1015550 in Plasma (Cmax)
nanomole/LiterBI 1015550 Severe renal impairmentBI 1015550 Normal renal function matched to severe renal impairmentBI 1015550 Moderate renal impairmentBI 1015550 Normal renal function matched to moderate renal impairment
Maximum Measured Concentration of R-BI 1015550 in Plasma (Cmax)399.46 ± NA464.19 ± NA367.36 ± NA380.43 ± NA
Statistical analysis
  • BI 1015550 Severe renal impairment vs BI 1015550 Normal renal function matched to severe renal impairment · Ratio of adjusted geometric means [%]: 86.06 · 90% CI 64.88 to 114.15Ratio \[%\] = (adjusted geometric mean of severe renal impairment / adjusted geometric mean matching control)\*100. Intra-matched pair geometric coefficient of variation (gCV) \[%\] = 30.5
  • BI 1015550 Moderate renal impairment vs BI 1015550 Normal renal function matched to moderate renal impairment · Ratio of adjusted geometric means [%]: 96.57 · 90% CI 56.80 to 164.16Ratio \[%\] = (adjusted geometric mean of moderate renal impairment / adjusted geometric mean matching control)\*100. Intra-matched pair geometric coefficient of variation (gCV) \[%\] = 66.2
PrimaryMaximum Measured Concentration of BI 1015550 in Plasma (Cmax)

Maximum measured concentration of BI 1015550 (mixture of R-(pharmacologically active) and S-(pharmacologically inactive) enantiomers, measured by a non-chiral assay) in plasma (Cmax) is reported. Geometric least square mean (adjusted geometric mean) and adjusted geometric standard error were calculated using an analysis of variance (ANOVA) model on the logarithmic scale. The pharmacokinetic (PK) endpoints were log-transformed (natural logarithm) prior to fitting the ANOVA model. This model included effects accounting for the following sources of variation: 'degree of renal impairment' as fixed effect as well as 'matched pair' as random effect. These quantities were then back-transformed to the original scale. The ratio of adjusted geometric means is calculated with patients with renal impairment as test groups and their respective matched controls as reference groups.

Time frame:
Within 2 hours (h) prior to drug administration and 0.5, 0.75, 1, 1.25, 1.5, 1.75, 2, 2.5, 3, 4, 6, 8, 10, 12, 14, 24, 36, 48, 72, 96, 120 and 144 h after drug administration.
Reported as:
Geometric least squares mean · nanomole/Liter
Maximum Measured Concentration of BI 1015550 in Plasma (Cmax)
nanomole/LiterBI 1015550 Severe renal impairmentBI 1015550 Normal renal function matched to severe renal impairmentBI 1015550 Moderate renal impairmentBI 1015550 Normal renal function matched to moderate renal impairment
Maximum Measured Concentration of BI 1015550 in Plasma (Cmax)404.41 ± NA486.36 ± NA359.75 ± NA397.56 ± NA
Statistical analysis
  • BI 1015550 Severe renal impairment vs BI 1015550 Normal renal function matched to severe renal impairment · Ratio of adjusted geometric means [%]: 83.15 · 90% CI 60.91 to 113.51Ratio \[%\] = (adjusted geometric mean of severe renal impairment / adjusted geometric mean matching control)\*100. Intra-matched pair geometric coefficient of variation (gCV) \[%\] = 33.8
  • BI 1015550 Moderate renal impairment vs BI 1015550 Normal renal function matched to moderate renal impairment · Ratio of adjusted geometric means [%]: 90.49 · 90% CI 52.40 to 156.26Ratio \[%\] = (adjusted geometric mean of moderate renal impairment / adjusted geometric mean matching control)\*100. Intra-matched pair geometric coefficient of variation (gCV) \[%\] = 68.5
SecondaryArea Under the Concentration-time Curve of R-BI 1015550 in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞)

Area under the concentration-time curve of R-BI 1015550 (the pharmacologically active R-enantiomer, measured by a chiral assay) in plasma over the time interval from 0 extrapolated to infinity (AUC0-∞) is reported. Geometric least square mean (adjusted geometric mean) and adjusted geometric standard error were calculated using an analysis of variance (ANOVA) model on the logarithmic scale. The pharmacokinetic (PK) endpoints were log-transformed (natural logarithm) prior to fitting the ANOVA model. This model included effects accounting for the following sources of variation: 'degree of renal impairment' as fixed effect as well as 'matched pair' as random effect. These quantities were then back-transformed to the original scale. The ratio of adjusted geometric means is calculated with patients with renal impairment as test groups and their respective matched controls as reference groups.

Time frame:
Within 2 hours (h) prior to drug administration and 0.5, 0.75, 1, 1.25, 1.5, 1.75, 2, 2.5, 3, 4, 6, 8, 10, 12, 14, 24, 36, 48, 72, 96, 120 and 144 h after drug administration.
Reported as:
Geometric least squares mean · hour*nanomole/Liter
Area Under the Concentration-time Curve of R-BI 1015550 in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞)
hour*nanomole/LiterBI 1015550 Severe renal impairmentBI 1015550 Normal renal function matched to severe renal impairmentBI 1015550 Moderate renal impairmentBI 1015550 Normal renal function matched to moderate renal impairment
Area Under the Concentration-time Curve of R-BI 1015550 in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞)3391.98 ± NA2638.63 ± NA3177.31 ± NA2333.59 ± NA
Statistical analysis
  • BI 1015550 Severe renal impairment vs BI 1015550 Normal renal function matched to severe renal impairment · Ratio of adjusted geometric means [%]: 128.55 · 90% CI 87.42 to 189.02Ratio \[%\] = (adjusted geometric mean of severe renal impairment / adjusted geometric mean matching control)\*100. Intra-matched pair geometric coefficient of variation (gCV) \[%\] = 39.8
  • BI 1015550 Moderate renal impairment vs BI 1015550 Normal renal function matched to moderate renal impairment · Ratio of adjusted geometric means [%]: 136.16 · 90% CI 88.41 to 209.69Ratio \[%\] = (adjusted geometric mean of moderate renal impairment / adjusted geometric mean matching control)\*100. Intra-matched pair geometric coefficient of variation (gCV) \[%\] = 52.1
SecondaryArea Under the Concentration-time Curve of BI 1015550 in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞)

Area under the concentration-time curve of BI 1015550 (mixture of R-(pharmacologically active) and S-(pharmacologically inactive) enantiomers, measured by a non-chiral assay) in plasma over the time interval from 0 extrapolated to infinity (AUC0-∞) is reported. Geometric least square mean (adjusted geometric mean) and adjusted geometric standard error were calculated using an analysis of variance (ANOVA) model on the logarithmic scale. The pharmacokinetic (PK) endpoints were log-transformed (natural logarithm) prior to fitting the ANOVA model. This model included effects accounting for the following sources of variation: 'degree of renal impairment' as fixed effect as well as 'matched pair' as random effect. These quantities were then back-transformed to the original scale. The ratio of adjusted geometric means is calculated with patients with renal impairment as test groups and their respective matched controls as reference groups.

Time frame:
Within 2 hours (h) prior to drug administration and 0.5, 0.75, 1, 1.25, 1.5, 1.75, 2, 2.5, 3, 4, 6, 8, 10, 12, 14, 24, 36, 48, 72, 96, 120 and 144 h after drug administration.
Reported as:
Geometric least squares mean · hour*nanomole/Liter
Area Under the Concentration-time Curve of BI 1015550 in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞)
hour*nanomole/LiterBI 1015550 Severe renal impairmentBI 1015550 Normal renal function matched to severe renal impairmentBI 1015550 Moderate renal impairmentBI 1015550 Normal renal function matched to moderate renal impairment
Area Under the Concentration-time Curve of BI 1015550 in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞)4280.84 ± NA3423.14 ± NA3941.06 ± NA3112.82 ± NA
Statistical analysis
  • BI 1015550 Severe renal impairment vs BI 1015550 Normal renal function matched to severe renal impairment · Ratio of adjusted geometric means [%]: 125.06 · 90% CI 85.27 to 183.40Ratio \[%\] = (adjusted geometric mean of severe renal impairment / adjusted geometric mean matching control)\*100. Intra-matched pair geometric coefficient of variation (gCV) \[%\] = 39.6
  • BI 1015550 Moderate renal impairment vs BI 1015550 Normal renal function matched to moderate renal impairment · Ratio of adjusted geometric means [%]: 126.61 · 90% CI 85.30 to 187.92Ratio \[%\] = (adjusted geometric mean of moderate renal impairment / adjusted geometric mean matching control)\*100. Intra-matched pair geometric coefficient of variation (gCV) \[%\] = 43.6

Adverse events

Collected over From the time of drug administration, until the end of the on-treatment period, up to 7 days. All-cause mortality was recorded from the time of drug administration until the end of trial, up to 2 weeks.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
BI 1015550 Severe renal impairment0/8 (0%)0/8 (0%)4/8 (50%)
BI 1015550 Normal renal function matched to severe renal impairment0/8 (0%)0/8 (0%)3/8 (37.5%)
BI 1015550 Moderate renal impairment0/8 (0%)0/8 (0%)2/8 (25%)
BI 1015550 Normal renal function matched to moderate renal impairment0/8 (0%)0/8 (0%)3/8 (37.5%)
Most frequent other events
Most frequent other events
EventBI 1015550 Severe renal impairmentBI 1015550 Normal renal function matched to severe renal impairmentBI 1015550 Moderate renal impairmentBI 1015550 Normal renal function matched to moderate renal impairment
HypertensionVascular disorders2/80/80/80/8
HaematomaVascular disorders0/81/80/81/8
DiarrhoeaGastrointestinal disorders0/80/81/80/8
COVID-19Infections and infestations1/80/80/80/8
NasopharyngitisInfections and infestations1/80/80/80/8
ContusionInjury, poisoning and procedural complications0/80/81/80/8
Lipase increasedInvestigations0/81/81/81/8
DizzinessNervous system disorders1/80/80/80/8
HeadacheNervous system disorders1/81/81/81/8

Baseline characteristics

Treated set (TS): included all participants who received trial medication.

Age, Continuous
Age, Continuous(Years)BI 1015550 Severe Renal ImpairmentBI 1015550 Moderate Renal ImpairmentBI 1015550 Normal Renal FunctionTotal
Mean66.4 ± 12.365.3 ± 10.360.7 ± 11.963.8 ± 11.6
Sex: Female, Male
Sex: Female, Male(Participants)BI 1015550 Severe Renal ImpairmentBI 1015550 Moderate Renal ImpairmentBI 1015550 Normal Renal FunctionTotal
Female43411
Male45615
Race (NIH/OMB)
Race (NIH/OMB)(Participants)BI 1015550 Severe Renal ImpairmentBI 1015550 Moderate Renal ImpairmentBI 1015550 Normal Renal FunctionTotal
American Indian or Alaska Native0000
Asian0000
Native Hawaiian or Other Pacific Islander0000
Black or African American0000
White881026
More than one race0000
Unknown or Not Reported0000
08

Study locations

1 site
  • CRS Clinical Research Services Kiel GmbH
    Kiel, 24105, Germany
09

References and documents

Related links

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — Clinical studies sponsored by Boehringer Ingelheim, phases I to IV, interventional and non-interventional, are in scope for sharing of the raw clinical study data and clinical study documents. Exceptions might apply, e.g. studies in products where Boehringer Ingelheim is not the license holder; studies regarding pharmaceutical formulations and associated analytical methods, and studies pertinent to pharmacokinetics using human biomaterials; studies conducted in a single center or targeting rare diseases (in case of low number of patients and therefore limitations with anonymization). For more details refer to: https://www.mystudywindow.com/msw/datatransparency

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2023 to primary completion in Aug 2023, 6 months.

Results were first posted in Nov 2025, 2 years 3 months after primary completion.

Of 213 industry-sponsored phase 1 interventional studies under Renal Insufficiency, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 15. This study's 6 months is below that.

Counting every sponsor, half of 231 studies reached it within 8 months; a quarter within 5 and three quarters within 16.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 30, 2023
First posted
Feb 8, 2023
StartActual
Feb 9, 2023
Primary completionActual
Aug 15, 2023
CompletionActual
Aug 15, 2023
Results first posted
Nov 28, 2025
Last update
Nov 28, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 28, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05718648
Responsible party
Sponsor
First posted
Feb 8, 2023
Start date
Feb 9, 2023
Primary completion
Aug 15, 2023
Completion
Aug 15, 2023
Results posted
Nov 28, 2025
Last update
Nov 28, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nerandomilast

Start the discussion